Tender: National Early Inflammatory Autoimmune Diseases Audit — 3‑Year NHS Clinical Audit for England, Wales and Jersey

About

The Authority is seeking a supplier to deliver the National Early Inflammatory Autoimmune Diseases Audit for NHS-funded care in England and Wales and publicly funded care in Jersey over an initial three-year period, with a core budget capped at £933,979.20 including VAT (£778,316.00 excluding VAT); bids exceeding this core budget will be rejected. The contract may be extended for up to 24 months on a pro rata basis (estimated up to £518,877 excluding VAT) and may include optional aspirational measures that could increase the overall ceiling to £6,417,788 excluding VAT (£7,701,346 including VAT) if invoked. The supplier will design and run a continuous prospective national clinical audit that captures and reports provider-level performance against NICE Quality Standard QS33 (Rheumatoid Arthritis in Adults), QS214 (Rare diseases) and other relevant standards, develop and maintain a minimum viable paediatric inflammatory arthritis pathway and dataset (aligned to the anticipated GIRFT Paediatric Inflammatory Arthritis Pathway guidance), manage an organisational survey to support quality improvement, support benchmarking and targeted improvement activity, consider individual-patient data linkages, ensure robust methodological and statistical input, engage clinicians, patients and stakeholders, and deliver outputs including near real-time interactive metrics, an annual state-of-the-nation report, validated PROMs, quality improvement resources and identification of outliers.